Redhill Historical Income Statement
| RDHL Stock | USD 0.39 0.01 2.50% |
Historical analysis of Redhill Biopharma income statement accounts such as Research Development of 3.3 M, Total Operating Expenses of 43.9 M, Income Before Tax of 25 M or Total Other Income Expense Net of 58 M can show how well Redhill Biopharma performed in making a profits. Evaluating Redhill Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Redhill Biopharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Redhill Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Redhill Biopharma is a good buy for the upcoming year.
Redhill |
About Redhill Income Statement Analysis
Redhill Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Redhill Biopharma shareholders. The income statement also shows Redhill investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Redhill Biopharma Income Statement Chart
Redhill Biopharma Income Statement is one of the three primary financial statements used for reporting Redhill's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Redhill Biopharma revenue and expense. Redhill Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Redhill Biopharma's Net Income is quite stable compared to the past year. Gross Profit is expected to rise to about 5.1 M this year, although the value of Selling General Administrative will most likely fall to about 18.4 M. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Redhill Biopharma. It is also known as Redhill Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Redhill Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Redhill Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.At this time, Redhill Biopharma's Net Income is quite stable compared to the past year. Gross Profit is expected to rise to about 5.1 M this year, although the value of Selling General Administrative will most likely fall to about 18.4 M.
Redhill Biopharma income statement Correlations
Click cells to compare fundamentals
Redhill Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Redhill Biopharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 2.5M | 9.0M | 18.1M | 8.2M | 2.0M | 3.2M | |
| Interest Expense | 438K | 12.8M | 16.6M | 41.3M | 367K | 348.7K | |
| Selling General Administrative | 11.5M | 25.4M | 76.6M | 55.0M | 28.9M | 18.4M | |
| Other Operating Expenses | 49.5M | 128.0M | 166.9M | 104.6M | 37.9M | 54.2M | |
| Operating Income | (43.2M) | (63.7M) | (81.1M) | (42.8M) | (31.4M) | (32.9M) | |
| Ebit | (43.2M) | (63.7M) | (81.1M) | (42.8M) | (31.4M) | (32.9M) | |
| Research Development | 17.4M | 16.5M | 29.5M | 7.3M | 3.5M | 3.3M | |
| Ebitda | (40.7M) | (54.7M) | (63M) | (34.6M) | (29.4M) | (30.8M) | |
| Total Operating Expenses | 47.2M | 91.2M | 117.5M | 71.3M | 34.4M | 43.9M | |
| Income Before Tax | (42.3M) | (76.2M) | (97.7M) | (71.7M) | 23.9M | 25.0M | |
| Total Other Income Expense Net | 897K | (12.5M) | (16.6M) | (28.8M) | 55.2M | 58.0M | |
| Net Income | (43.6M) | (89.0M) | (114.3M) | (59.2M) | 23.9M | 25.1M | |
| Income Tax Expense | 1.3M | 12.8M | 16.6M | (12.4M) | (2.0) | (1.9) | |
| Total Revenue | 6.3M | 64.4M | 85.8M | 61.8M | 6.5M | 6.2M | |
| Gross Profit | 4.0M | 27.5M | 36.4M | 28.5M | 3.1M | 5.1M | |
| Cost Of Revenue | 2.3M | 36.9M | 49.4M | 33.3M | 3.5M | 3.3M | |
| Net Income From Continuing Ops | (42.3M) | (76.2M) | (97.7M) | (71.7M) | 23.9M | 25.1M | |
| Net Income Applicable To Common Shares | (38.8M) | (42.3M) | (76.2M) | (97.7M) | (88.0M) | (83.6M) | |
| Net Interest Income | 5K | (12.6M) | (16.6M) | (41.2M) | (2.2M) | (2.3M) | |
| Interest Income | 443K | 176K | 51K | 140K | 94K | 176.2K | |
| Selling And Marketing Expenses | 18.3M | 49.3M | 11.4M | 9.1M | 2.1M | 2.0M | |
| Reconciled Depreciation | 1.2M | 8.7M | 18.1M | 8.2M | 2.0M | 1.9M |
Currently Active Assets on Macroaxis
When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Redhill Stock analysis
When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 4 | Revenue Per Share 1.008 | Quarterly Revenue Growth (0.96) | Return On Assets (0.16) | Return On Equity (8.84) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.